Jubilant Ingrevia Ltd. · NSE:JUBLINGREA
Jubilant Ingrevia — Q2 FY2022 Earnings Presentation
25 slides from Jubilant Ingrevia's earnings presentation, Oct 19, 2021
Slide 1: Financial Results Quarter & Half Year Ended 30th September, 2021
Financial Results Quarter & Half Year Ended 30th September, 2021
Slide 2: Disclaimer
Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f
Slide 3: Conference Call Details
Conference Call Details Date : October 19, 2021 Time : 05:00 pm IST Conference Dial-In Numbers + 91 22 6280 1141 Universal Access: + 91 22 7115 8042 USA: 1 866 746 2133 Toll Free Number: UK: 0 808 101 1573 Singapore: 800 101 2045 Hong Kong: 800 964 448 Available from October 19 to October 26, 2021 R
Slide 4: Chairmen's Message
Chairmen’s Message Mr. Shyam S Bhartia Mr. Hari S Bhartia Chairman Co-Chairman “With immense pleasure, I would like to announce that we have delivered yet another strong financial performance in Q2’FY22 and reported our highest ever revenue during the Quarter & Half Year ended 30th Sept’21. Supply d
Slide 5: Financial Highlights: Key Financial Parameters
Financial Highlights1 : Key Financial Parameters Highlights ₹ 1,223 Cr. ₹ 202 Cr. 16.5% ₹ 111 Cr. 9.1% ₹ 7.0 Q2’FY22 Sales EBITDA EBITDA (%) PAT PAT (%) EPS 56% YoY 44% YoY (135) bps 43% YoY (79) bps 43% YoY Highlights ₹ 784 Cr. ₹ 140 Cr. 17.9% ₹ 77 Cr. 9.9% ₹ 4.8 Q2’FY21 2 Sales EBITDA EBITDA (%) P
Slide 6: Jubilant Ingrevia: Business Segments & Integrated Operations
Jubilant Ingrevia: Business Segments & Integrated Operations Integrated Operations… Vertical integration across the value chain enables cost competitive advantage Nutrition & For Vitamin B3 (Niacinamide & Niacin), 100% in-house sourcing of Beta Picoline Speciality Nutrition & Health Life Science H
Slide 7: Q2'FY22 Results Analysis
Q2'FY22 Results Analysis INGREVIA
Slide 8: Jubilant Ingrevia – Q2'FY22 Financial Highlights
Jubilant Ingrevia – Q2'FY22 Financial Highlights Particulars1 Q2'FY212 Q2'FY22 YoY (%) • Revenue grew by 56% on YoY basis, driven by robust growth in volume and Revenue prices. Speciality Chemicals 252 295 17% • Speciality Chemicals revenue grew by 17% YoY driven by volume growth across Nutrition &
Slide 9: Speciality Chemicals - Key Highlights Q2'FY22
Speciality Chemicals- Key Highlights Q2’FY22 China Industry shutdown led by pollution control measures and energy consumption targets is driving global volatility and higher input prices in almost all key raw material & Fuel prices and also affecting availability. We are focusing on sourcing and
Slide 10: Speciality Chemicals Segment Highlights – Q2'FY22
Speciality Chemicals Segment Highlights – Q2'FY22 Particulars1 Q2'FY212 Q2'FY22 YoY (%) Revenue 252 295 17% Specialty Chemicals revenue grew by 17% on YoY basis Reported EBITDA 71 71 0% driven by higher volume across product segments Reported EBITDA Margin (%) 28.1% 24.1% North America revenue g
Slide 11: Nutrition & Health Solutions - Key Highlights Q2'FY22
Nutrition & Health Solutions - Key Highlights Q2’FY22 During the quarter, there has been reduction of African Swine Fever in China which has resulted into overall demand improvement of Vitamin B3 (Niacinamide & Niacin). We were in a position to place higher volume both QoQ as well as YoY basis.
Slide 12: Nutrition & Health Solutions Segment Highlights – Q2'FY22
Nutrition & Health Solutions Segment Highlights – Q2'FY22 Particulars1 Q2'FY212 Q2'FY22 YoY (%) Nutrition and Health Solutions revenue grew by 43% Revenue 125 179 43% on YoY basis. Reported EBITDA 28 35 23% • Growth was driven by prices and growth in Reported EBITDA Margin (%) 22.6% 19.5% Niacinam
Slide 13: Life Sciences Chemicals - Key Highlights Q2 FY'22
Life Sciences Chemicals - Key Highlights Q2 FY’22 Life Sciences Chemical market condition remained favourable due to supply disruption in European and China market driven by force majeure by key supplier of Acetyl products. Though Acetic Acid price during end of quarter increased sharply however
Slide 14: Life Science Chemicals Segment Highlights – Q2'FY22
Life Science Chemicals Segment Highlights – Q2'FY22 Particulars1 Q2'FY212 Q2'FY22 YoY (%) Life Sciences Chemicals revenue grew by 84% on YoY basis Revenue 406 749 84% Reported EBITDA 40 103 160% • Life Sciences Chemical revenue growth was driven by Reported EBITDA Margin (%) 9.7% 13.8% higher pric
Slide 15: H1'FY22 Results Analysis
H1'FY22 Results Analysis INGREVIA
Slide 16: Jubilant Ingrevia – H1'FY22 Financial Highlights
Jubilant Ingrevia – H1'FY22 Financial Highlights Particulars1 H1'FY212 H1'FY22 YoY (%) • Revenue grew by 56% on YoY basis, driven by robust growth in volume and Revenue prices. Speciality Chemicals 509 600 18% • Speciality Chemicals revenue grew by 18% YoY driven by volume growth across Nutrition &
Slide 17: Speciality Chemicals Segment Highlights – H1'FY22
Speciality Chemicals Segment Highlights – H1'FY22 Particulars1 H1'FY212 H1'FY22 YoY (%) Specialty Chemicals revenue grew by 18% on YoY basis Revenue 509 600 18% driven by higher volume across product segments Reported EBITDA 140 155 11% North America revenue grew significantly, percentage Report
Slide 18: Nutrition & Health Solutions Segment Highlights – H1'FY22
Nutrition & Health Solutions Segment Highlights – H1'FY22 Particulars1 H1'FY212 H1'FY22 YoY (%) Nutrition and Health Solutions revenue grew by 26% Revenue 274 346 26% on YoY basis. Reported EBITDA 60 61 3% Reported EBITDA Margin (%) 21.8% 17.7% • Growth was driven by prices and growth in Niacinami
Slide 19: Life Science Chemicals Segment Highlights – H1'FY22
Life Science Chemicals Segment Highlights – H1'FY22 Particulars1 H1'FY212 H1'FY22 YoY (%) Life Sciences Chemicals revenue grew by 93% on YoY basis Revenue 737 1,422 93% • Life Sciences Chemical revenue growth was driven by Reported EBITDA 63 287 353% higher prices and volume growth in Acetic Anhyd
Slide 20: Debt Profile – As on 30th September, 2021
Debt Profile – As on 30th September, 2021 Particulars1 31-Mar-21 30-Jun-21 30-Sep-21 Long Term Borrowings 548 227 218 Short Term Borrowings - 230 45 Total Gross Debt 548 457 263 Cash & Equivalent 117 70 70 Total Net Debt 431 386 193 QoQ change -10% -50% Gross Debt and Net Debt reduction of Rs 193
Slide 21: Balance Sheet – Key Parameters/Ratios (Pro-Forma)
Balance Sheet – Key Parameters/Ratios (Pro-Forma2) Return On Capital Employed (RoCE) Return on Equity Asset / Turnover and Return On Asset (RoA) 2.0x 2.8x 26.6% 33.2% 16.0% 20.2% 9.4% (%age) (%age) (%age) 16.4% FY'21 H1'FY22 FY'21 H1'FY22 FY'21 H1'FY22 FY'21 H1'FY22 FY'21 H1'FY22 Asset / Turnover FY
Slide 22: Business outlook
Business outlook Demand of most of our Products is expected to remain strong in H2. Though input costs are increasing our business teams are confident to pass on the incremental costs by working closely with customers We will continue to make efforts to deleverage the Balance Sheet and reduce th
Slide 23: For More Information
For More Information For Investors: Pavleen Taneja Siddharth Rangnekar Ph: +91 120 436 1002| 21 CDR India E-mail: [email protected] Ph: +91 22 6645 1209 E-mail: [email protected] For Media: Sudhakar Safaya Clayton Dsouza Ph: +91 120 436 1034 Madison Public Relations E-mail: sudhakar.safa
Slide 24: Our Vision, Values, Promise and Philosophy
Our Vision, Values, Promise and Philosophy OUR PHILOSOPHY Caring Sharing Growing 24
Slide 25: Appendix: Income Statement – Q2 & H1'FY22
Appendix : Income Statement – Q2 & H1’FY22 Particulars1 Q2'FY212 Q2'FY22 YoY (%) H1'FY212 H1'FY22 YoY (%) Total Revenue from Operations 784 1,223 56% 1,520 2,367 56% Speciality Chemicals 252 295 17% 509 600 18% Nutrition & Health Solutions 125 179 43% 274 346 26% Life Science Chemicals 406 749 84% 7